| Price | $1.15 |
| Year Range | $1.03 – $1.41 |
| Market Cap | $68M |
| Industry | Biotechnology |
What Is Pliant Therapeutics’s AI Stock Analysis?
Pliant Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Pliant Therapeutics’s momentum in near-real time.
Pliant Therapeutics (PLRX) has an AltIndex AI Score of 58/100, currently a Hold signal. The AI Score distills Pliant Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Pliant Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Pliant Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving PLRX’s AI Score?
Fundamentals
Net income for the last quarter was $-22M. This represents a decrease of 11.63% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -48.33%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-22M. This represents a decrease of 12.11% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -47.27%, suggesting positive year-over-year growth.
See Pliant Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $1.15. This is equal to the stock price a month ago, showing short-term stability. However, compared to a year ago, there is a decrease of 19.58%, which could be a cause for long-term concern. The trend is bullish. The current SMA10 is $1.07, which is higher than the previous SMA10 of $1.06. This indicates a potential upward trend in price movement. The RSI is 83.3, indicating a potentially overbought (bearish) condition.
See the full technical analysis and price prediction.
Alternative data
Pliant Therapeutics has an estimated 3 open positions. This number is down by -25% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Pliant Therapeutics is neutral. Pliant Therapeutics has an estimate of 4,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Pliant Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Pliant Therapeutics has 490 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Pliant Therapeutics’s market sentiment.
Frequently Asked Questions: Pliant Therapeutics AI Stock Analysis
Pliant Therapeutics's AltIndex AI Score is 58/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Pliant Therapeutics a Hold (58/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Pliant Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the PLRX AI Score or sign up to read the full thesis.
